Description
CagriSema – Dual GLP-1 & Amylin Analogue Research Compound
CagriSema is a dual-agonist peptide blend combining semaglutide (a GLP-1 receptor agonist) with cagrilintide (a long-acting amylin analogue). It is under investigation for its synergistic effects on appetite regulation, glucose control, and weight loss.
CagriSema works by engaging two complementary pathways: semaglutide slows gastric emptying, enhances insulin secretion, and reduces appetite; cagrilintide mimics amylin’s effects on satiety and meal termination. The dual mechanism is intended to provide stronger metabolic control and greater weight reduction than either agent alone.
Key Features & Research Applications
🍽 Appetite Suppression & Satiety:
Dual action helps reduce food intake through enhanced fullness and slower digestion.
📉 Weight Loss & Fat Reduction:
Designed for potent body-weight reduction in obesity models, leveraging combined GLP-1 + amylin effects.
🩺 Glycemic Regulation:
Improves blood glucose control and HbA1c levels in preclinical and clinical settings.
❤️ Metabolic Health:
Potential benefits for insulin sensitivity, lipid profile, and cardiometabolic markers.
📊 Clinical & Translational Research:
Currently in Phase III trials for obesity and type 2 diabetes, showing promising weight-loss outcomes. Drugs.com+2American Diabetes Association+2
Product Details
-
Name: CagriSema (cagrilintide + semaglutide)
-
Form: Lyophilized powder or blend formulation
-
Purity: ≥ 98% for each component
-
Dosage Example: 10 mg (or 10 mg / 10 mg in blended formats)
-
Appearance: White to off-white powder
-
Storage: Store in a cool, dry environment; refrigerate after reconstitution; freeze aliquots for longer term stability
-
Packaging: Sterile vials for laboratory use
-
Verification: Batch tested with Certificates of Analysis (COA)
